Immunitas Therapeutics

📍 Waltham, United States🗓 Founded 2019👥 30 employees💰 Last funded Nov 2019
Biotechnology Research🌐 immunitastx.com
Website LinkedIn
Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Switzerland
1
United States
1
Netherlands
1
Frequently asked questions
Who invested in Immunitas Therapeutics?
Immunitas Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Immunitas Therapeutics last raise funding?
The most recent investment in Immunitas Therapeutics recorded on gritt.io was in November 2019.
When was Immunitas Therapeutics founded?
Immunitas Therapeutics was founded in 2019.
What industry is Immunitas Therapeutics in?
Immunitas Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Immunitas Therapeutics based?
Immunitas Therapeutics is headquartered in Waltham, United States.